Merck: 'therapeutic breakthrough' for antibody-conjugate

(CercleFinance.com) - On Tuesday Merck announced that the FDA had granted breakthrough therapy status to its antibody-conjugate project for the treatment of a specific form of bronchial cancer.


The pharmaceutical group claims to have obtained this status from the US health agency for sacituzumab tirumotecan (sac-TMT) in the treatment of certain patients with advanced or metastatic non-squamous non-small cell lung cancer with EGFR gene mutations.

More specifically, the decision concerns patients expressing a deletion of exon 19 or exon 21 whose disease has progressed during or after chemotherapy accompanied by treatment with tyrosine kinase inhibitors

The investigational drug conjugate antibody Sac-TMT, developed in collaboration with Kelun-Biotech, is currently in ten Phase 3 clinical trials, either as a single agent or in combination with the immunotherapy Keytruda.


Copyright (c) 2024 CercleFinance.com. All rights reserved.